Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Stage 1 hypertension strongly predicts 10-year CVD events

19 May 2019

Stage 1 hypertension but not elevated blood pressure (BP) appears to be associated with a significant increase in the incidence of fatal and nonfatal cardiovascular disease (CVD) events over a 10-year follow-up, according to data from the ATTICA study.

The analysis involved 3,042 randomly selected Greek adults aged 18–89 years. Hypertension status was defined based on mean systolic/diastolic blood pressure and the most recent 2017 ACC/AHA guidelines: high normal blood pressure (HNBP; systolic, 120–139 mm Hg; diastolic, 80–89 mm Hg; no prior history of high blood pressure), elevated BP (systolic, 120–129 mm Hg; diastolic, <80 mm Hg) and stage 1 hypertension (systolic, 130–139 mm Hg; diastolic, 80–89 mm Hg).

In the cohort, the prevalence rates of HNBP, elevated BP and stage 1 hypertension were 44.6 percent (n=626), 29.0 percent (n=408) and 15.5 percent (n=218), respectively.

Incident fatal and nonfatal CVD events during follow-up of 10 years occurred in 98 patients (15.6 percent) in the HNBP group, 49 (12.0 percent) in the elevated BP group and 49 (22.5 percent) in the stage 1 hypertension group as compared with 49 (6.3 percent) in the normotension group (p<0.0001 for all).

Relative to normal BP, HNBP and stage 1 hypertension contributed to an increased risk of 10-year CVD. The risk increased by 1.5-fold with HNBP (adjusted hazard ratio [aHR], 1.49; 95 percent CI, 1.00–2.20) and by twofold with stage 1 hypertension (aHR, 1.90; 1.16–3.08). The risk increase was particularly pronounced in males (aHR, 2.03; 1.08–3.83).

On the other hand, elevated BP was not associated with an increased risk of developing 10-year CVD events (aHR, 1.28; 0.82–2.02).

In light of a notable increased risk of 10-year fatal and nonfatal CVD events associated with HNBP and stage 1 hypertension, researchers called for the implementation of targeted primary and secondary prevention interventions that may deter both CVD and related adverse health outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.